Recursion is collaborating with the FDA on the drug candidate REC-4881.
2 reports, 2 independent
Updated Sep 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Recursion is collaborating with the FDA on the drug candidate REC-4881.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Recursion (United States)
company in Salt Lake City, United States
- FDA
Related events
- Recursion Pharmaceuticals is listed on Nasdaq, and BioCardia, Inc. is a company developing therapeutics in the United States.
- The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.
- MarketBeat is providing analyst ratings for Recursion Pharmaceuticals.